Clinical Trial Update: A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants [Phase 1]

View source ↗

Summary

Phase 1 safety study of BAY3283142 in healthy Chinese participants to assess single-dose and multiple-dose safety, sponsored by Bayer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Non-proliferative Diabetic Retinopathy

Drugs mentioned

• BAY3283142

Snippet

Sponsor: Bayer | Conditions: Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy | Phase 1 | Status: COMPLETED